Speaker illustration

Professor Pieter Doevendans

University Medical Center Utrecht, Utrecht (Netherlands (The))

Member of:

European Society of Cardiology

Pieter Doevendans became a cardiologist in Maastricht (Chair Hein Wellens). In 1993-1994 he had the opportunity to study molecular cardiology at UCSD San Diego where the work on stem cells started. The work was completed in Maastricht and provided the basis for a thesis on the promoter of the atrial MLC2 gene. Upon return in the Netherlands he worked with Christine Mummery and Hans Clevers (Hubrecht Laboratory). In the meantime he remained active as an interventional cardiologist initially in Maastricht, but from 2002 on in Utrecht. Here he was appointed full professor in Cardiology in 2004 and head of the department in 2005. The focus is on Cardiac Failure, regenerative medicine and genetics. He was funded by various national and international foundations. Thus far (2019) he published more than 750 peer reviewed papers and 13 books. He is an active member of the European Society of Cardiology where he performed various tasks.

Genetics

Event: ESC Congress 2023

Topic: Genetics, Epigenetics, ncRNA

Session type: Moderated ePosters

Thumbnail

IPS and other cell models

Event: ESC Congress 2023

Topic: Stem Cells, Cell Cycle, Cell Senescence, Cell Death

Session type: Moderated ePosters

Thumbnail

Cell-cell interactions

Event: ESC Congress 2022

Topic: Heart Failure

Session type: Moderated ePosters

Thumbnail

Gene editing for the heart: progress and hurdles

Event: Frontiers in CardioVascular Biomedicine 2022

Topic: Genetics, Epigenetics, ncRNA

Session type: Symposium

Thumbnail

Cardiomyopathies: translating innovations

Event: ESC Congress 2019

Topic: Cardiomyopathies

Session type: Symposium

Thumbnail

Is there any progress in risk stratification for sudden cardiac death?

Event: ESC Congress 2018

Topic: Risk Factors and Risk Assessment

Session type: Advances in Science

Thumbnail

Detection of subclinical atherosclerosis

Event: EuroPrevent 2017

Topic: Risk scores

Session type: Symposium

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb